Naltrexone in Obsessive-Compulsive Disorder: an Open- Label Trial

authors:

avatar Aram Hamidi 1 , * , avatar Bijan Jahanguiri 2 , avatar Mehdi Nasr Nasr Esfahanini 3 , avatar Mahbuobeh Dadfar 3

Tehran Psychiatric Institute, Iran University of Medical Sciences, Tehran, Iran, +98-2177537842
Department of Pharmacology, Tehran University of Medical sciences, Tehran, Iran
Tehran Psychiatric Institute, Iran University of Medical sciences, Tehran, Iran
Iranian Journal of Psychiatry and Behavioral Sciences: Vol.1, issue 1; 16-21
published online: January 30, 2007
article type: Original Article
received: October 30, 2006
accepted: December 04, 2006

how to cite: Hamidi A, Jahanguiri B, Nasr Esfahanini M N, Dadfar M. Naltrexone in Obsessive-Compulsive Disorder: an Open- Label Trial. Iran J Psychiatry Behav Sci. 2007;1(1): 16-21. 

Abstract

Objective: In spite of introduction of novel drugs, Obsessive-Compulsive Disorder (OCD) has still found no suitable treatment. On the other hand, high rates of co-morbidity of OCD with bipolar spectrum disorders are increasingly recognized. Mood switching and development of rapid cycling with antidepressants are significant problems in these patients. From this viewpoint, introducing a non-antidepressant anti-OCD drug has great theoretical and clinical importance. In this open-label clinical trial we evaluated the effects of naltrexone on OCD symptoms
Method: In this study, 23 OCD outpatients treated with a fixed dose of clomipramie, fluoxetine, or both, for at least 3 months before trial underwent treatment with naltrexone, 25 to 100 milligrams a day as adjunctive treatment. Change in symptoms was evaluated by Yale-Brown Obsessive-Compulsive Scale (YBOCS), Persian version, administered at baseline and at the end of the 2 months trial.
Results: Seven patients dropped out of the study before the end of the 2 months: 4 patients for non-response and 3 patients for intolerable side effects. Sixteen patients, 9 females and 7 males, completed the study. The most frequent co-morbid disorders found in these patients were bipolar spectrum disorders (68.7%). Non-parametric (Wilcoxon Signed Ranks Test) and parametric (paired t-test) analyses both showed significant reductions in YBOCS ratings after naltrexone treatment (P<0.001). Two patients remained symptom free over 6 months after discontinuation of all medications
Conclusion: Although small sample size and open design of the trial make the results tentative, it appears that naltrexone may be effective on at least certain subgroups of OCD patients, especially those with both OCD and bipolar spectrum disorders. Long-term effects of the drug after discontinuation should be addressed in future double-blind studies.
 
 

Fulltext

Full text is available in the PDF.

References

  • 1.

    References are available in the PDF.